BioWorld

Nov. 16, 2009

View Archived Issues

Ziopharm's Bet: Cancer Pills Will Beat I.V.; Off-On Method Intrigues

"Ruthlessly efficient" is how Jonathan Lewis, CEO and chief medical officer of Ziopharm Oncology Inc., last week described his firm's approach to research and financial management. Read More

Money Raised Year to Date

Read More

No Public Funds or Partners: Can Istodax Be New Approval Model?

Read More

Enzon's Specialty-Biz Offload Leaves Convertible Overhang

Read More

Money Raised By Biotech in 2009

Read More

Week in Review

Read More

Word on the Street

Read More

Week in Washington

Read More

FDA Approvals for October

Read More

Phase I Clinical Trials Update: October 2009

Read More

Phase II Clinical Trials Update: October 2009

Read More

Pivotal/Phase III Clinical Trials Update: October 2009

Read More

American College of Rheumatology

Read More

American Association for the Study of Liver Disease

Read More

Non-U.S. Clinical Trials And Regulatory Actions: October 2009

Read More

FDA Submissions, Approvals And Other Actions: October 2009

Read More

Stock Gainers and Losers For The Week

Read More

BioWorld Stock Report For Public Biotechnology Companies

Read More